BR112019003406A2 - antagonistas do receptor androgênico tio-hidantoína para o tratamento de câncer - Google Patents
antagonistas do receptor androgênico tio-hidantoína para o tratamento de câncerInfo
- Publication number
- BR112019003406A2 BR112019003406A2 BR112019003406-4A BR112019003406A BR112019003406A2 BR 112019003406 A2 BR112019003406 A2 BR 112019003406A2 BR 112019003406 A BR112019003406 A BR 112019003406A BR 112019003406 A2 BR112019003406 A2 BR 112019003406A2
- Authority
- BR
- Brazil
- Prior art keywords
- androgen receptor
- thiohydantoin
- antagonists
- cancer treatment
- need
- Prior art date
Links
- 102000001307 androgen receptors Human genes 0.000 title abstract 2
- 108010080146 androgen receptors Proteins 0.000 title abstract 2
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical compound O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000003936 androgen receptor antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377932P | 2016-08-22 | 2016-08-22 | |
| US62/377,932 | 2016-08-22 | ||
| PCT/IB2017/055063 WO2018037342A1 (en) | 2016-08-22 | 2017-08-22 | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019003406A2 true BR112019003406A2 (pt) | 2019-05-21 |
Family
ID=60009664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019003406-4A BR112019003406A2 (pt) | 2016-08-22 | 2017-08-22 | antagonistas do receptor androgênico tio-hidantoína para o tratamento de câncer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190209539A1 (https=) |
| EP (1) | EP3500259A1 (https=) |
| JP (1) | JP2019528290A (https=) |
| KR (1) | KR20190040030A (https=) |
| CN (1) | CN109640986A (https=) |
| AU (1) | AU2017316756A1 (https=) |
| BR (1) | BR112019003406A2 (https=) |
| CA (1) | CA3034449A1 (https=) |
| MA (1) | MA45992A (https=) |
| MX (1) | MX2019002097A (https=) |
| RU (1) | RU2019108092A (https=) |
| WO (1) | WO2018037342A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3666772A4 (en) * | 2017-08-07 | 2021-01-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST |
| WO2020113088A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| JP7464613B2 (ja) | 2019-02-01 | 2024-04-09 | 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 | ジアリールチオヒダントイン化合物結晶 |
| CN115403624B (zh) * | 2022-09-30 | 2024-08-27 | 上海应用技术大学 | 一种二芳基硫代乙内酰脲化合物及其制备方法与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011218173C1 (en) * | 2010-02-16 | 2015-04-16 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| US9365542B2 (en) * | 2012-10-26 | 2016-06-14 | Memorial Sloan-Kettering Cancer Center | Modulators of resistant androgen receptor |
-
2017
- 2017-08-22 BR BR112019003406-4A patent/BR112019003406A2/pt not_active Application Discontinuation
- 2017-08-22 AU AU2017316756A patent/AU2017316756A1/en not_active Abandoned
- 2017-08-22 EP EP17778334.7A patent/EP3500259A1/en not_active Withdrawn
- 2017-08-22 CA CA3034449A patent/CA3034449A1/en not_active Abandoned
- 2017-08-22 MA MA045992A patent/MA45992A/fr unknown
- 2017-08-22 CN CN201780051671.2A patent/CN109640986A/zh active Pending
- 2017-08-22 WO PCT/IB2017/055063 patent/WO2018037342A1/en not_active Ceased
- 2017-08-22 MX MX2019002097A patent/MX2019002097A/es unknown
- 2017-08-22 US US16/327,703 patent/US20190209539A1/en not_active Abandoned
- 2017-08-22 KR KR1020197007833A patent/KR20190040030A/ko not_active Ceased
- 2017-08-22 JP JP2019510593A patent/JP2019528290A/ja active Pending
- 2017-08-22 RU RU2019108092A patent/RU2019108092A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190040030A (ko) | 2019-04-16 |
| JP2019528290A (ja) | 2019-10-10 |
| WO2018037342A1 (en) | 2018-03-01 |
| MX2019002097A (es) | 2019-05-15 |
| CN109640986A (zh) | 2019-04-16 |
| RU2019108092A3 (https=) | 2020-11-30 |
| CA3034449A1 (en) | 2018-03-01 |
| MA45992A (fr) | 2019-06-26 |
| RU2019108092A (ru) | 2020-09-22 |
| US20190209539A1 (en) | 2019-07-11 |
| AU2017316756A1 (en) | 2019-02-21 |
| EP3500259A1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230272A1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| SA518391624B1 (ar) | Ror- منظمات جاما | |
| CY1126152T1 (el) | Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων | |
| BR112018014222A2 (pt) | método de tratamento da glomerulopatia c3 | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| BR112016002970A2 (pt) | biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio | |
| IL281809A (en) | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | |
| BR112019003406A2 (pt) | antagonistas do receptor androgênico tio-hidantoína para o tratamento de câncer | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| NZ739392A (en) | Methods for treating hepcidin-mediated disorders | |
| BR112017024966A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
| PH12019500254A1 (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| MX390484B (es) | Construcción biespecífica que se une a cd33 y cd3 para usarse en tratamiento de leucemia mieloide | |
| BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
| BR112019007763A2 (pt) | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção | |
| BR112015026257A2 (pt) | terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata | |
| MY201535A (en) | Therapeutic compounds | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| BR112017016428A2 (pt) | ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório? | |
| MX2021003689A (es) | Farmacos precursores de antagonistas del peptido relacionado con el gen para calcitonina (gcrp). | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112019004684A2 (pt) | combinação de agonistas de fxr | |
| WO2022093552A8 (en) | Rev-erb agonists | |
| MX2016008968A (es) | Compuestos organicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |